Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ajmaline is a class Ia antiarrhythmic alkaloid derived from the root of Rauwolfia serpentina and other plant sources. It is primarily used to manage various forms of tachycardias, including atrial fibrillation in patients with Wolff–Parkinson–White syndrome and well-tolerated monomorphic ventricular tachycardias. Ajmaline is also widely used as a diagnostic agent to unmask the type-1 Brugada syndrome electrocardiogram pattern. Its mechanism of action involves blocking sodium channels (notably the Nav 1.5 channel), which lengthens cardiac action potentials and slows conduction velocity, thereby stabilizing abnormal heart rhythms. Ajmaline also has additional effects on potassium (including hERG) and calcium channels, further prolonging repolarization and refractory periods[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ajmaline.